Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings

Stock Information for Aytu BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aytu BioPharma Inc.

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.